RIPK1-IN-9

CAS No. 2682889-57-0

RIPK1-IN-9( —— )

Catalog No. M35690 CAS No. 2682889-57-0

RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 398 In Stock
5MG 345 In Stock
10MG 473 In Stock
25MG 705 In Stock
50MG 923 In Stock
100MG 1256 In Stock
200MG 1674 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RIPK1-IN-9
  • Note
    Research use only, not for human use.
  • Brief Description
    RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.
  • Description
    RIPK1-IN-9 (example 45), a dihydronaphthyridone compound, is a potent and selective RIPK1 inhibitor. RIPK1-IN-9 inhibits U937 cell (IC50=2 nM) and L929 cell (IC50=1.3 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    RIP kinase
  • Recptor
    RIP kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2682889-57-0
  • Formula Weight
    472.51
  • Molecular Formula
    C26H25FN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C=2C(=NC=C(C2)C3=CC=4N(C=C3)N=C(N)N4)CCN1CC5=C(OC6CCCC6)C=CC(F)=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fusheng Zhou, et al. Dihydronaphthyridone compounds, their preparation and pharmaceutical uses. WO2021160109A1.
molnova catalog
related products
  • GSK-583

    A potent, selective and orally bioavailable RIPK2 kinase inhibitor with IC50 of 5 nM and 2 nM for human and rat RIP2, respectively.

  • RIPK1-IN-7

    RIPK1-IN-7 is a potent and selective inhibitor of RIPK1(Kd of 4 nM and an enzymatic IC50 of 11 nM),andexhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.

  • CSLP37

    CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay.